First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard of care for the first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as single agents or combined with chemotherapy. The evidence sustaining their role for poor performance status (ECOG PS ≥2) pa...

Full description

Saved in:
Bibliographic Details
Published in:Transl Lung Cancer Res
Main Authors: Facchinetti, Francesco, Di Maio, Massimo, Perrone, Fabiana, Tiseo, Marcello
Format: Artigo
Language:Inglês
Published: AME Publishing Company 2021
Subjects:
Original Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264315/
https://ncbi.nlm.nih.gov/pubmed/34295688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-21-15
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items